AngioDynamics, Inc. (NASDAQ:ANGO) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 6, H.C. Wainwright reiterated its Buy rating on AngioDynamics (NASDAQ ...
AngioDynamics Inc (NASDAQ:ANGO) is set to release its Q2 2025 earnings on Jan 8, 2025. The consensus estimate for Q2 2025 revenue is $70.93 million, and the earnings are expected to come in at -$0.22 ...
Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16. Fourth-quarter sales totaled $70.98 million, beating the ...
AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance. First-quarter revenue rose 12.1% to $75.7 ...
AngioDynamics, Inc. ANGO recently announced the initiation of a clinical study, AMBITION BTK, comparing the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty with ...
The hold thesis remains for AngioDynamics following its latest set of numbers and impeding macro-headwinds. Shares have shown high correlation to long-dated treasury yields in FY22 and this continues ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On ...
AngioDynamics presents with deflationary tailwinds bought on by a softening in key materials used in its manufacturing process. Despite this, investors continue to reward low-beta, highly profitable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback